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complex (Figure 1B). Second, the second-order binding
reaction for GAP complex formation may be weak and,
thus, driven faster by elevated concentrations of RGS9.
Testing these hypotheses will yield new information
about the cellular and molecular details of RGS function.
Implications for Non-Retinal Neuronal Timing Circuits
and for Therapeutics
GPCR cascades are implicated in a variety of neuronal
circuits with strict timing requirements: for example, the
basal ganglia are widely understood to be involved in
precision timing of locomotion and other behaviors, and
evidence has been presented that a splice variant of
the photoreceptor RGS, RGS9-2, acting through dopa-
minergic D1 and D2 GPCR cascades, modulates psy-
chostimulant-induced locomotion and reward behavior
(Rahman et al., 2003). One important implication of the
experiments of Krispel et al. is that the expression levels
of different RGSs in specific neuronal subpopulations
are likely to be tightly regulated in order to achieve preci-
sion timing of behavior. Another implication of broad
significance is that the expression levels per se of RGSs
may become proper targets for therapeutic interventions
in diseases of such timing circuits. In sum, the bottom
line is simple and powerful: RGS expression levels are
critical for timing, and in GPCR signaling ‘‘timing is every-
thing’’ (Shea et al., 2000).
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Thank Your Endocannabinoids
Endocannabinoids can mediate neuroprotection, but
it is not known how. In this issue of Neuron, Monory
et al. use mutant mice and localized viral targeting to
produce conditional knockouts of the cannabinoid
CB1 receptor. They show that protection against
kainic acid-induced seizures and cell death is con-
ferred by CB1Rs on hippocampal glutamatergic nerve
terminals.
Epileptic seizures reflect states of pathological hyperex-
citability and hypersynchronous activity in large neuro-
nal networks. Broadly speaking, seizures arise from an
imbalance of two fundamental antagonistic neuronal
motive forces—excitation and inhibition—toward exci-
tation. But the underlying mechanisms may be very
complex and, in addition to alterations in the strength
of excitatory and inhibitory chemical synapses, may
involve electrical gap junctions, neuronal network oscil-
lations, and rewiring of the neuronal circuits. The hippo-
campus is one of the most seizure-prone brain regions,
perhaps because it typically rests near the tipping point
of the balance and is susceptible to numerous forms of
plasticity. Whatever their etiology, seizures are highly
disruptive to normal brain functions, and if severe and
prolonged, can lead to very bad outcomes, including
neuronal cell death. Intrinsic biological mechanisms
that protect against seizures are therefore of great theo-
retical and practical interest.
Endogenous cannabinoids (‘‘endocannabinoids’’) are
the natural agonists of membrane-bound, G protein-
coupled receptors that mediate the actions of drugs,
such as marijuana, derived from the cannabis plants.
The principal cannabinoid receptor subtype in the
CNS, CB1R, is predominantly localized on or near syn-
aptic terminals, and its activation inhibits synaptic trans-
mitter release. The two major endocannabinoids are
arachidonyl-ethanolamide (anandamide) and 2-arachi-
donyl glycerol (2-AG). They are produced by neuronal
enzymatic activity and generally serve as intercellular
messengers, often traveling in the ‘‘retrograde’’ direc-
tion to the incoming synaptic input. CB1Rs are widely
dispersed throughout the brain in specific association
with well-defined cell types in the different regions,
and this accounts for the variety of behavioral effects
caused by the exogenous cannabinoids. Several years
ago, Panikashvili et al. (2001) reported that experimental
closed-head injury produced an elevation in 2-AG and
that exogenous administration of 2-AG reduced the
brain edema and hippocampal cell death associated
with such injuries. This was direct in vivo evidence for
a neuroprotective effect of an endocannabinoid. In this
issue of Neuron, Monory et al. (2006) now ask and an-
swer novel questions about the cellular mechanisms of
endocannabinoid-mediated neuroprotection.
In an earlier investigation, Lutz, Marsicano, and
colleagues (Marsicano et al., 2003) reported that mice
lacking CB1 (CB12/2) experienced kainic acid (KA)-
induced seizures that were much more severe than
those experienced by wt or heterozygotic CB1+/2
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tive. Using a Cre/LoxP system in which Cre recombinase
was under the control of the CamKIIa gene (not ex-
pressed in interneurons), they then created conditional
knockout mice in which CB1Rs were deleted in all prin-
cipal glutamatergic neurons of the forebrain (cortical
and subcortical), but were spared in GABAergic inter-
neurons (and cerebellum). The KA-induced seizures ex-
perienced by the conditional knockouts were as severe
as those in the full CB12/2mice, and neuronal cell death
was also greater in these animals. Thus, the CB1Rs as-
sociated with forebrain principal neurons were impli-
cated as major factors for endogenous neuroprotection.
As a corollary, the remaining CB1Rs appeared to offer
no neuroprotection. Moreover, because the hippocam-
pus is the region that is most vulnerable to KA excitotox-
icity (see Ben-Ari and Cossart, 2000), the results sug-
gested that the CB1Rs expressed by hippocampal
glutamatergic neurons might be key to neuroprotection.
There was no direct evidence for either of these latter
two conclusions, however.
In expanding upon their previous work, Monory et al.
(2006) turned first to conditional CB1 deletions. They
have created two new lines of mice: one lacking CB1
only in cortical (including hippocampal) glutamatergic
neurons (Glu-CB12/2) and one lacking CB1 in forebrain
GABAergic interneurons (GABA-CB12/2). They com-
pared these mice with those lacking CB1 in all forebrain
glutamatergic neurons (now referred to as CamKII-
CB12/2). A major finding was that the Glu-CB12/2
mice have the same enhanced seizure vulnerability as
the CB12/2 and CamKII-CB12/2 mice, which is consis-
tent with the idea that CB1R on cortical glutamatergic
cells are key elements in the defense against KA-
induced excitotoxicity. In contrast, the GABA-CB12/2
mice had no seizure-related deficits; their seizure
susceptibility was the same as the wt mice. Moreover,
the anticonvulsant benzodiazepine, diazepam (which
enhances GABA-mediated inhibition), was equally
effective in protecting against KA-induced seizures in
wt and CB12/2 mice, suggesting that the CB1 system
does not influence GABAergic transmission during
these seizures.
Is the hippocampus the main recipient of the endo-
cannabinoid-mediated neuroprotection, and if so which
neurons are involved? Using a combination of immuno-
histochemical staining and double in situ hybridization
for CB1 and the vesicular glutamate transporter,
VGluT1, Monory et al. identified the mossy cell, a gluta-
matergic cell type in the dentate gyrus, as a focal point,
by virtue of its relatively high and consistent expression
of CB1 and suspected role in epileptogenesis (Ratzliff
et al., 2002). Mossy cells (not be confused with mossy fi-
bers, which are the granule cell axons) provide a strong
excitatory drive to the granule cells, and their synaptic
output is suppressed by cannabinoids. To see whether
these cells are involved in behavioral seizure protection,
the authors injected a Cre-expressing adeno-associ-
ated virus (AAV-Cre) into the mossy cell region of the
dentate gryus of CB1-floxed mice. This produced
aCB1 deletion confined largely to this region and nearby
CA1 and CA3. Amazingly, these mice suffered signifi-
cantly worse seizures when treated with KA than wt or
AAV-GFP virus-treated animals. This is the first solid ev-idence that CB1Rs confined to a limited cell group can
play a significant role in epileptogenesis.
Hence, the powerful combination of molecular lesion-
ing methods employed by Monory et al. strongly sup-
ports the emerging picture that a strong epileptogenic
influence causes excessive output of glutamate, which,
if unchecked, leads to development of seizures and
widespread neuronal death. Normally, however, gluta-
mate output and its deleterious sequelae are limited by
the inhibitory actions of endocannabinoids on glutama-
tergic terminals. These findings fuel hope of capitalizing
on the endocannabinoid-mediated neuroprotection to
develop novel therapies for treatment of seizures or
stroke.
The finding of unaltered seizure susceptibility in
GABA-CB12/2 mice, while not necessarily a paradox,
is a bit unexpected. Epileptic activity can readily be in-
duced in experimental models by decreasing the
strength of GABA inhibition, and this mechanism may
contribute to the human disease. As noted earlier, anti-
convulsants often enhance GABAergic responses. The
naive expectation would be that activation of CB1Rs
on GABAergic terminals, and the resultant suppression
of GABA transmission, would exacerbate seizures. On
these grounds, CB1 absence in the GABA-CB12/2
mice would be protective. Why is removal of the
CB1Rs on GABAergic terminals not associated with an
obvious seizure phenotype? For one thing, the CB1Rs
are not associated with all GABAergic interneurons,
but only a well-defined subset: the cholescystokinin
(CCK)-containing basket cells (Freund et al., 2003). The
other major basket cell type, the parvalbumin (PV)-con-
taining cells (PV and CCK groups are mutually exclu-
sive), do not express CB1, and evidently the activity of
these and other non-CB1-expressing interneurons was
sufficient to account for the anticonvulsant actions of di-
azepam. The GABA-CB12/2 animals will serve as most
interesting subjects for unraveling the behavioral func-
tions of the prominent GABAergic eCB system.
Obvious questions stemming from the Monory et al.
(2006) study include whether endocannabinoids are
also protective in other seizure models, and what
exactly explains the neuroprotection. Inhibition of gluta-
mate release is a likely mechanism, and the CamKII-
CB12/2 mice do release glutamate more readily than
wt mice (Marsicano et al., 2003), but the mechanism of
CB1R-mediated neuroprotection has not been unam-
biguously demonstrated. Some conclusions are com-
plicated by species and preparation differences (e.g.,
Mechoulam and Lichtman, 2003, for a brief overview).
There are other subtle issues as well. Where does the
neuroprotective endocannabinoid come from, and
what is its identity?
Monory et al. (2006), carefully checked to see that their
GABA-CB12/2 animals lacked CB1Rs on the interneu-
ron terminals by testing for the reduction of inhibitory re-
sponses by neuronally released endocannabinoids
(‘‘DSI’’) and showing that it was absent. Surprisingly,
they do not report having done the analogous test on
the Glu-CB12/2 or CamKII-CB12/2 animals. Reduction
of excitatory responses by neuronally released endo-
cannabinoids (DSE), in other words, should have been
absent. One must assume that they thought of doing
this test, so its omission is noteworthy. Deletion of
The Rodent Orbitofrontal Cortex
Gets Time and Direction
The orbitofrontal cortex (OFC) helps direct decision
making through its flexible coding of reward and eco-
nomic value. In this issue ofNeuron, papers byRoesch
et al. and Feierstein et al. demonstrate the importance
of temporal and spatial features to processing in the
rodent OFC.
Imagine you are thirsty. You can get a small drink imme-
diately, or if you wait 10 minutes you can get a larger
drink that will more fully quench your thirst. Do you drink
now or wait for the larger drink? Alternatively, imagine
that you can cash-in a ticket today for $100 or wait
2 weeks and get $125. Do you cash it in now or wait?
Across multiple species there is a substantial preference
for immediate rewards over delayed rewards, even
when the immediate reward is of lower magnitude (see
Figure 1). The process through which rewards are deval-
ued over increasing delays is referred to as ‘‘temporal
discounting’’ and is a critical component of neuroeco-
nomic models. Lesions to certain brain areas can
change the slope of the temporal discounting function.
Among such brain regions, the orbitofrontal cortex
(OFC) appears unique, in that lesions to the OFC in
rodents lessen the bias toward immediate rewards
(Winstanley et al., 2004).
In the present issue of Neuron, Roesch, Taylor and
Schoenbaum (Roesch et al., 2006) demonstrate that
OFC cells are sensitive to the temporal features of re-
wards in a manner consistent with temporal discount-
ing. The authors trained rodents in a task in which the
spatial location of the reward predicted the delay pre-
ceding reward delivery. OFC cells that responded to re-
wards were common. In 40% of these reward-sensitive
cells, rewards delivered after a short delay produced
significantly greater responses than those delivered af-
ter a long delay, demonstrating a temporal discounting
effect. In another 17% of cells, the opposite effect was
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showing that a synthetic CB1R agonist did not suppress
excitatory transmission in CamKII-CB12/2 or Glu-CB12/2
animals (although it did in wt). The question, therefore, is
not whether the mutants are the genuine articles, but
how and how readily the endocannabinoids that nor-
mally activate CB1Rs on glutamate terminals are mobi-
lized. Unlike DSE in the cerebellum, which is prominent
and easily induced by physiologically relevant stimuli
(Kreitzer and Regehr, 2001), DSE in the hippocampus
is not generated by stimuli that produce DSI (Ohno-
Shosaku et al., 2002) and at best only modestly reduces
glutamate release. Endocannabinoids are generated by
both Ca2+- and G protein-coupled receptor pathways,
which may differ biochemically (Edwards et al., 2006).
It will be important to work out the biochemical and
indeed the cellular source of neuroprotective endo-
cannabinoids.
What is the neuroprotective endocannabinoid? Glu-
tamate stimulates production of 2-AG but not ananda-
mide in the hippocampus (Stella et al., 1997). Moreover,
a recent report finds CB1Rs expressed on the hippo-
campal glutamatergic axons and a key biochemical
component of the 2-AG synthetic pathway positioned
on dendritic spines directly across from the terminals
(Katona et al., 2006). The 2-AG system is therefore ide-
ally positioned and poised to mediate neuroprotection.
The prediction is that 2-AG levels should be increased
during seizures. Yet direct endocannabinoid measure-
ments by Marsicano et al. (2003) did not confirm this
expectation: KA treatment increased anandamide but
not 2-AG levels. It seems there are still subtleties
regarding endocannabinoids, their regulation and
function, that provide ample opportunities for future
discoveries.
Finally, it was once cynically remarked that the lesion
approach to understanding the brain is like trying to
learn how a television set works by disabling one tube
at a time with a hammer (those unfamiliar with ‘‘tube’’
in this context should consult an older person). Seeing
the picture dissolve into a mass of wavy lines following
the breaking of a particular tube might lead to the con-
clusion that it had functioned primarily as the ‘‘wavy
line suppressor’’; the intricacy of the truth obscured by
the dramatic effects caused by the malfunction. It is
worth bearing in mind that, although the hammers and
tubes grow smaller, such concerns do not entirely go
away.
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